Xcout Intel
NBE-Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to NBE-Therapeutics among biotechnology companies — ranked by similarity to what NBE-Therapeutics actually does, not by market-cap band.
Subscribe to see NBE-Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NBE-Therapeutics
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
NBE-Therapeutics at a glance
NBE-Therapeutics is a biotechnology company headquartered in Switzerland. It has raised at least $23.8M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $20.7M in November 2016. Xcout tracks 3 named people at NBE-Therapeutics, including Olof Prause (Chief Operating Officer).
NBE-Therapeutics leadership
- Olof PrauseChief Operating Officer
- Andy BrossChief Financial Officer
- Carl DeutschChief Scientific Officer
NBE-Therapeutics funding rounds
At least $23.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $20.7M | — | |
| Series A | $3.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 NBE-Therapeutics competitors
Ranked by semantic similarity — how close each company is to NBE-Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Tubulis is a biotechnology organization headquartered in Munich that generates uniquely matched antibody-drug conjugates with superior biophysical properties.
Similar biotechnology company
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Biotech
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Similar biotechnology company
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Biotech
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Similar biotechnology company
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Similar biotechnology company
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Similar biotechnology company
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Similar biotechnology company
Mythic Therapeutics, Inc. is a biotechnology research company headquartered in Waltham, Massachusetts. The company is dedicated to developing a proprietary platform to enhance the effectiveness of antibody-drug conjugates and other antibody-based therapeutics.
Similar biotechnology company
VAXIMM AG is a biotech company headquartered in Basel, Switzerland, that focuses on developing a new class of cytotoxic immunotherapies and clinical-stage targeted treatments through its subsidiaries.
Biotech
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NBE-Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NBE-Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →